These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 20546817)
1. Comorbidities, quality of life and patients' willingness to pay for a cure for type 2 diabetes in Taiwan. Chang K Public Health; 2010 May; 124(5):284-94. PubMed ID: 20546817 [TBL] [Abstract][Full Text] [Related]
2. Study of Patients' Willingness to Pay for a Cure of Chronic Obstructive Pulmonary Disease in Taiwan. Chen YT; Ying YH; Chang K; Hsieh YH Int J Environ Res Public Health; 2016 Mar; 13(3):. PubMed ID: 26938547 [TBL] [Abstract][Full Text] [Related]
3. Willingness to pay for drug abuse treatment: results from a contingent valuation study in Taiwan. Tang CH; Liu JT; Chang CW; Chang WY Health Policy; 2007 Jul; 82(2):251-62. PubMed ID: 17084480 [TBL] [Abstract][Full Text] [Related]
4. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Blumenschein K; Johannesson M Ann Allergy Asthma Immunol; 1998 Feb; 80(2):189-94. PubMed ID: 9494453 [TBL] [Abstract][Full Text] [Related]
5. A valuation of patients' willingness-to-pay for insulin delivery in diabetes. Guimarães C; Marra CA; Colley L; Gill S; Simpson SH; Meneilly GS; Queiroz RH; Lynd LD Int J Technol Assess Health Care; 2009 Jul; 25(3):359-66. PubMed ID: 19619355 [TBL] [Abstract][Full Text] [Related]
6. Willingness to pay for weight-control treatment. Liu JT; Tsou MW; Hammitt JK Health Policy; 2009 Jul; 91(2):211-8. PubMed ID: 19167128 [TBL] [Abstract][Full Text] [Related]
7. Economic costs of diabetes in the U.S. In 2007. American Diabetes Association Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683 [TBL] [Abstract][Full Text] [Related]
8. [The burden of depressive disorders in Germany - results from the European Study of the Epidemiology of Mental Disorders (ESEMeD)]. Günther OH; Friemel S; Bernert S; Matschinger H; Angermeyer MC; König HH Psychiatr Prax; 2007 Sep; 34(6):292-301. PubMed ID: 17806016 [TBL] [Abstract][Full Text] [Related]
9. Quality of life, treatments, and patients' willingness to pay for a complete remission of cervical cancer in Taiwan. Lang HC; Chang K; Ying YH Health Econ; 2012 Oct; 21(10):1217-33. PubMed ID: 21905153 [TBL] [Abstract][Full Text] [Related]
10. Patient awareness of prognosis, patient-family caregiver congruence on the preferred place of death, and caregiving burden of families contribute to the quality of life for terminally ill cancer patients in Taiwan. Tang ST; Liu TW; Tsai CM; Wang CH; Chang GC; Liu LN Psychooncology; 2008 Dec; 17(12):1202-9. PubMed ID: 18521969 [TBL] [Abstract][Full Text] [Related]
11. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Glasziou P; Alexander J; Beller E; Clarke P; Health Qual Life Outcomes; 2007 Apr; 5():21. PubMed ID: 17462100 [TBL] [Abstract][Full Text] [Related]
12. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Smith AF; Pitt AD; Rodruiguez AE; Alio JL; Marti N; Teus M; Guillen S; Bataille L; Barnes JR Ophthalmic Epidemiol; 2005 Aug; 12(4):233-42. PubMed ID: 16033744 [TBL] [Abstract][Full Text] [Related]
13. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. Delfino M; Holt EW; Taylor CR; Wittenberg E; Qureshi AA J Am Acad Dermatol; 2008 Sep; 59(3):439-47. PubMed ID: 18639364 [TBL] [Abstract][Full Text] [Related]
14. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513 [TBL] [Abstract][Full Text] [Related]
15. Valuation of the risk of SARS in Taiwan. Liu JT; Hammitt JK; Wang JD; Tsou MW Health Econ; 2005 Jan; 14(1):83-91. PubMed ID: 15386665 [TBL] [Abstract][Full Text] [Related]
16. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus. Guo JJ; Gibson JT; Gropper DM; Oswald SL; Barker KN Am J Manag Care; 1998 Oct; 4(10):1433-46. PubMed ID: 10338736 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282 [TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339 [TBL] [Abstract][Full Text] [Related]
19. Estimation of the relationship between body mass index and EQ-5D health utilities in individuals with type 2 diabetes: evidence from the population-based KORA studies. Hunger M; Schunk M; Meisinger C; Peters A; Holle R J Diabetes Complications; 2012; 26(5):413-8. PubMed ID: 22699110 [TBL] [Abstract][Full Text] [Related]
20. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study. Davis WA; Knuiman MW; Hendrie D; Davis TM Intern Med J; 2006 Mar; 36(3):155-61. PubMed ID: 16503950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]